Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

• Main Authors: Viktor Rotbain Curovic (Author), Morten B. Houlind (Author), Tine W. Hansen (Author), Jesper Eugen-Olsen (Author), Jens Christian Laursen (Author), Mie K. Eickhoff (Author), Frederik Persson (Author), Peter Rossing (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Elevated soluble urokinase plasminogen activator receptor (suPAR) is highly associated with increased risk of diabetic complications. Dapagliflozin is a drug inhibiting the sodium-glucose co-transporter 2 in the kidney to decrease blood glucose, while also decreasing risk of kidney disea...